Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

ClinicalTrials.gov ID: NCT06911112

Public ClinicalTrials.gov record NCT06911112. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Study identification

NCT ID
NCT06911112
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
200 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 30, 2025
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027
Last update posted
Aug 10, 2026

2025 – 2027

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
Neurocrine Clinical Site Huntsville Alabama 35801 Recruiting
Neurocrine Clinical Site Bryant Arkansas 72022 Recruiting
Neurocrine Clinical Site Glendale California 91206 Recruiting
Neurocrine Clinical Site Irvine California 92614 Withdrawn
Neurocrine Clinical Site Redlands California 92373 Recruiting
Neurocrine Clinical Site San Francisco California 94107 Recruiting
Neurocrine Clinical Site Hollywood Florida 33024 Recruiting
Neurocrine Clinical Site Miami Florida 33174 Active, not recruiting
Neurocrine Clinical Site Tampa Florida 33634 Recruiting
Neurocrine Clinical Site Atlanta Georgia 30318 Recruiting
Neurocrine Clinical Site Boston Massachusetts 02131 Withdrawn
Neurocrine Clinical Site Saint Charles Missouri 63304 Active, not recruiting
Neurocrine Clinical Site New York New York 10029 Recruiting
Neurocrine Clinical Site The Bronx New York 10461 Active, not recruiting
Neurocrine Clinical Site Mason Ohio 45040 Recruiting
Neurocrine Clinical Site DeSoto Texas 75115 Recruiting
Neurocrine Clinical Site Charlottesville Virginia 22903 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06911112, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 10, 2026 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06911112 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →